Accuray Incorporated
$ 0.59
5.55%
24 Feb - close price
- Market Cap 66,744,000 USD
- Current Price $ 0.59
- High / Low $ 0.63 / 0.57
- Stock P/E N/A
- Book Value 0.45
- EPS -0.31
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.70 %
- 52 Week High 2.12
- 52 Week Low 0.50
About
Accuray Incorporated designs, develops and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa and the rest of the Asia Pacific region. The company is headquartered in Sunnyvale, California.
Analyst Target Price
$2.52
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-11-05 | 2025-08-13 | 2025-04-30 | 2025-02-05 | 2024-11-06 | 2024-08-14 | 2024-05-01 | 2024-01-31 | 2023-11-07 | 2023-08-09 | 2023-04-26 |
| Reported EPS | -0.1076 | -0.1392 | 0.01 | -0.01 | 0.02 | -0.04 | 0.03 | -0.06 | -0.1 | -0.03 | -0.03 | 0.01 |
| Estimated EPS | -0.11 | -0.06 | 0.02 | -0.04 | -0.04 | -0.06 | 0.03 | -0.01 | -0.05 | -0.05 | 0.01 | -0.01 |
| Surprise | 0.0024 | -0.0792 | -0.01 | 0.03 | 0.06 | 0.02 | 0 | -0.05 | -0.05 | 0.02 | -0.04 | 0.02 |
| Surprise Percentage | 2.1818% | -132% | -50% | 75% | 150% | 33.3333% | 0% | -500% | -100% | 40% | -400% | 200% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARAY
2026-02-22 10:49:25
Accuray has partnered with Limbus AI to augment its adaptive radiotherapy capabilities by integrating Limbus AI's AI-driven auto contouring algorithms. This collaboration aims to streamline the treatment planning process, specifically by automating the critical and time-consuming step of defining tumor borders and organs at risk. This integrated offering is expected to be available in 2023, enhancing efficiency and enabling more personalized patient care with Accuray's existing technologies.
2026-02-17 22:58:18
Accuray Inc (ARAY) has announced its intention to offer 7 million shares of its common stock for sale, allowing existing shareholders to divest their holdings. The company, which specializes in advanced radiation therapy systems like the CyberKnife, faces financial challenges including a negative EPS, high leverage, and declining margins, with an Altman Z-Score indicating potential bankruptcy risk. Investors are closely watching the market's response to this offering and the stock's future performance.
2026-02-17 11:27:36
Accuray has published an updated investor presentation on its investor relations website, as disclosed in a Form 8-K filing on February 17, 2026. Company representatives are scheduled to present these contents to analysts and investors on or after the same date. The presentation, which includes forward-looking statements, provides summary information about the company.
2026-02-17 11:27:36
Accuray Inc. has released its Q2 FY2026 10-Q report, detailing significant financial and operational challenges. The report shows declines in revenue and profitability, impacted by increased costs, lower product sales, and macroeconomic factors like geopolitical tensions affecting the China region. The company expects continued challenges through fiscal year 2026.
2026-02-09 21:59:59
Accuray (ARAY) has announced a delay in filing its Form 10-Q for the quarter ended December 31, 2025, due to errors found in its remaining performance obligations disclosure from previous filings. The company expects to submit the report within a five-day extension and states that these errors are not anticipated to affect its Balance Sheets, Statements of Operations, or Cash Flows. Accuray also notes that this is a one-off issue and does not foresee a significant change in its operational results compared to the prior year.
2026-02-07 19:58:28
Wall Street Zen downgraded Accuray (NASDAQ:ARAY) from "hold" to "sell" on Saturday, February 7, 2026, contributing to a MarketBeat consensus rating of "Hold" with an average price target of $2.00. The company reported quarterly EPS of ($0.11), meeting estimates, and revenue of $102.24 million, but continues to show negative net margins and strained profitability. Despite institutional investment, shares opened at $0.62, currently trading with a market cap of approximately $70.27 million.
